Chronic granulomatous disease (CGD) is a rare congenital disorder characterized by recurrent, life-threatening infections and exuberant granuloma formation. Impaired phagocyte killing caused by dysfunction of any of the components of the reduced NADPH oxidase complex may result in clinical disease [1] . Patients with CGD have recurrent infections with a very specific subset of catalase-producing bacteria and fungi, including Staphylococcus aureus, Serratia marcescens, Burkholderia cepa-
Chronic granulomatous disease (CGD) is characterized by severe recurrent infections with
Staphylococcus aureus, certain gram-negative rods, Nocardia species, and fungi. When infections with the same species recur, they may represent relapses or new infections. We collected organisms from infections that occurred between 1992 and 2000 in patients with CGD and determined the biochemical phenotypes, in vitro antibiotic susceptibility patterns, and pulsed-field gel electrophoresis (PFGE) patterns of the organisms causing the initial and recurrent infections. Recurrence of infection with Burkholderia cepacia or Serratia marcescens was caused by a new strain in 9 of 10 cases ( ). Recurrent S. aureus infections were caused by new strains in 7 of 8 P p .001 cases (
). In patients with CGD, recurrence of infection with the same bacterial species after appropriate P p .006 antibiotic therapy usually represents new infection.
Chronic granulomatous disease (CGD) is a rare congenital disorder characterized by recurrent, life-threatening infections and exuberant granuloma formation. Impaired phagocyte killing caused by dysfunction of any of the components of the reduced NADPH oxidase complex may result in clinical disease [1] . Patients with CGD have recurrent infections with a very specific subset of catalase-producing bacteria and fungi, including Staphylococcus aureus, Serratia marcescens, Burkholderia cepa-cia, and Nocardia and Aspergillus species. In the absence of antibiotic prophylaxis, patients develop severe infections approximately yearly. Liver and lungs are involved in a large number of these infections; of 368 patients with CGD in the United States followed up in one study, 39% developed liver abscesses, and 24% developed lung infections [2] . Although the microbiological spectrum of these infections is limited, it has not been clear whether these patients become infected and then harbor persistent strains of these organisms or whether patients are repeatedly infected by different strains from the environment. The answer to the latter question has important implications for duration and intensity of therapy, use of prophylaxis, and recommendations about exposure to environmental hazards.
liver infection between 1992 and 2001. Of the 60 infections for which isolates were obtained, 13 were due to S. marcescens, 15 to B. cepacia, 7 to B. gladiolii, and 25 to S. aureus. Approximately one-third of the patients had recurrent infections caused by the same species of organism as the initial infection. Patients who had had at least 2 discrete episodes of culture-positive bacterial infection caused by the same species of organism and separated by at least 3 months were included in the present study. Eighteen recurrences were seen in 11 patients. Because 3 patients had 11 recurrence each, 14 sets of isolates were available.
Infections were treated with administration of intravenous antibiotics for 4 weeks, or longer if necessary for evidence of infection on imaging studies to disappear. Infections were considered to have been adequately treated when cultures became negative and computed tomographic or magnetic resonance images showed complete resolution or stability in 2 consecutive imagings. Before and after treatment of an acute infection, patients received prophylactic trimethoprim-sulfamethoxazole, 5 mg/kg orally twice daily [3, 4] , often accompanied by itraconazole, 5 mg/kg once daily [5] . Approximately one-half of the patients were receiving subcutaneous interferon-g when they developed recurrences. Four patients were excluded from the study because of nonviability of the stored frozen strains from their samples. Recurrent fungal infections, which are also seen in patients with CGD, were not included in this study.
Bacterial isolates. Isolates were obtained by culture of samples collected through diagnostic procedures at otherwise sterile sites (lung or liver biopsy, fine-needle aspiration, and bronchoalveolar lavage) or of blood samples or samples collected intraoperatively from wounds. Organisms were identified using standard phenotypic characteristics and biochemical tests. Biochemical phenotypes and antibiotic susceptibility patterns were obtained using MicroScan panels read on an Autoscan IV (Dade Behring). We used gram-negative and gram-positive breakpoint combination panels that provided both identification and antibiotic susceptibility results. After identification, pathogenic isolates were stored in tryptic soy broth-glycerol at Ϫ80ЊC. Biochemical and antibiotic susceptibility determinations for all included isolates were repeated when pulsed-field gel electrophoresis (PFGE) was performed, so that isolates from initial and recurrent infections in the same patient could be compared simultaneously.
Molecular typing was performed by PFGE. Organisms were grown overnight in brain-heart infusion broth with shaking. Aliquots of 500 mL were pelleted and resuspended in 100 mL of cell-suspension buffer (GenePath system reagent; Bio-Rad Laboratories). For gram-negative organisms, 5 mL of proteinase K was added and the solution was held at 37ЊC for 10-15 min; then 4 mL of 20% SDS, 4 mL of lysozyme, and 130 mL of 1.5% agarose were added, and the solution was warmed in a 55ЊC water bath. The mix was immediately pipetted into 50-mL-well plug molds (Bio-Rad) and solidified at 4ЊC for 5-10 min. Plugs were transferred to tubes with 500 mL of lysis buffer and 25 mL of proteinase K for gentle shaking overnight at 37ЊC. The next day, the plugs were heated at 50ЊC for 2 h and washed once with preheated distilled water and then 3 times with dilute Tris-EDTA buffer (1:4 concentration). All washes were done for 15 min at 50ЊC with gentle shaking. Plugs were incubated with 1ϫ New England Biolabs buffer #2 for 15-30 min at room temperature and then digested with 50 U of XbaI/plug for 4.5-5 h at 37ЊC or with 40 U of SpeI overnight at 37ЊC. For S. aureus, 4 mL of lysostaphin and 125 mL of agarose were added to the cell suspension, and the solution was gently mixed and transferred to the plug molds. After solidification, plugs were transferred to 500 mL of lysis buffer and held at 37ЊC with gentle shaking for 1 h. Twenty-five microliters of proteinase K was added, and the temperature was increased to 50ЊC for another hour; then the plugs were washed 4 times with dilute Tris-EDTA buffer for 15 min at 50ЊC. Plugs were incubated with 1ϫ New England Biolabs buffer #4 for 15 min and then digested for 2 h at room temperature with 80 U of SmaI. Both gramnegative and staphylococcal plugs were loaded onto 0.9% agarose gels and run on a contour-clamped homogeneous electric field system using 0.5ϫ Tris-borate-EDTA buffer for 20 h at an initial starting time of 2.2 s and a final stopping time of 35 s. All gels were stained with ethidium bromide and photographed under UV light.
PFGE analysis was performed in accordance with current guidelines [6] [7] [8] . The presence of у3 unshared bands was considered to indicate that strains were unrelated, whereas strain differences of р2 bands were considered to indicate that strains were the same or closely related. A difference in antibiotic susceptibility was acknowledged only when the change was from resistant to susceptible, rather than from resistant to intermediately resistant or intermediately resistant to susceptible. For biochemical profiles (expressed as a numerical code), we compared the results of the array of tests used in the MicroScan identification panels. These reflected 18 biochemical reactions for S. aureus and 24 reactions for gram-negative bacilli.
Statistical analysis. To perform any statistical analysis, we had to generate an arbitrary projected rate of relapse. Although it is often assumed that recurrence of infection caused by the same species as the initial infection is due to relapse, firm data are rarely provided to support this assumption. We conservatively hypothesized that 60% of recurrent infections would be due to relapses and the remainder to new infections. This estimate predicted that a significant difference would be detected if the relapse rate was actually !15%. Comparisons between our findings and expected values were made using 1-sample proportion tests. We considered significance to be indicated by a 2-tailed P value !.05 ( ; 95% confidence interval). a p .05 
NOTE. AC, amoxicillin-clavulanic acid; Ak, amikacin; Am, ampicillin; AS, ampicillin-sulbactam; Az, aztreonam; Ce, cefazolin; Cf, cefuroxime; Ci, ciprofloxacin; Cp, cefepime; Cx, ceftriaxone; Cz, ceftazidime; Gm, gentamicin; I, intermediately resistant; Im, imipenem; LLL, left lower lobe; Lv, levofloxacin; Me, meropenem; PFGE, pulsed-field gel electrophoresis; Pi, piperacillin; R, resistant; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe; S, susceptible; Te, tetracycline; To, tobramycin; TS, trimethoprim-sulfamethoxazole.
a API 20E (bioMé rieux).
RESULTS

Patients.
Our study included 11 patients with CGD who had 18 recurrences total; 14 sets of isolates were available, from recurrent infections with S. marcescens, B. cepacia, and S. aureus. Six of the patients had an X-linked inheritance pattern, and the other 5 had autosomal defects, with approximately equal distribution for each organism. Patient ages ranged from 8 to 29 years ( , years). Infections were often mean ‫ע‬ SD 22 ‫ע‬ 5.7 in the same site (e.g., liver or left lower lobe) in a given patient and often had similar clinical presentations.
Pneumonia. Four patients had episodes of S. marcescens pneumonia (9 episodes total; table 1). Patient 2 had 3 infections, all in the left lower lobe. The interval between recurrences ranged from 5 months to 4 years. Among the 9 S. marcescens isolates, biochemical phenotypes differed by р2 reactions. Judging by these differences in biochemical code, 3 of the 4 patients had recurrent infection with strains that were different from those that caused the initial infection. All Serratia isolates were susceptible to trimethoprim-sulfamethoxazole, and the antibiograms of these isolates were indistinguishable, except for some variation in tetracycline susceptibility. Only 1 of the 4 patients could have been considered, on the basis of the antibiogram data, to have a recurrence caused by a strain different from that causing the initial infection; the isolates from patient 2 changed from tetracycline resistant to susceptible. PFGE showed that all strains from all episodes were unique (figure 1).
Five patients had episodes of B. cepacia pneumonia (10 episodes total; table 2). The interval between recurrences ranged from 8 months to 4 years. Biochemical profiles were highly variable; only 2 of the 10 biochemical profiles were identical (those for isolates 6-17 and 7-18), and these were strains from 2 different patients. This variability may reflect the recent recognition that B. cepacia has 6 genomic variants [9] known to have biochemical differences. Biochemical profiles suggested that all 5 recurrent episodes were caused by strains different from those causing the initial episodes. All of the B. cepacia isolates were susceptible to trimethoprim-sulfamethoxazole, except for those from patient 6 (6-16 and 6-17). Antibiotic susceptibility profiles for the 10 strains showed variability to aztreonam, ceftazidime, imipenem, piperacillin, and cefepime. The recurrent strains from 3 of the 5 patients (patients 2, 3, and 6) would have been considered, on the basis of these antibiograms, to be different from the initial strains. PFGE showed that in 4 of the 5 patients, the recurrence was caused by a different strain (figure 2).
Liver abscesses. Five patients had Staphylococcus aureus liver abscesses (13 cases total; table 3). The interval between recurrences ranged from 5 months to 6 years. Patient 10 had 3 episodes of infection, and patient 11 had 4 episodes. The isolates showed differences primarily in 3 biochemical tests; by these profiles, all 5 patients appeared to have had recurrences that were caused by strains different from those causing the initial infections. However, because different patients had strains with the same biochemical profile, the discriminatory power of these profiles was questionable. Only 1 S. aureus isolate (10-28) was resistant to trimethoprim-sulfamethoxazole, and 1 other (9-25) was resistant to oxacillin. Three of 8 strains that caused recurrences would have been considered, on the basis of significant differences in antibiograms, to be the same as the isolate causing the initial infection (isolates 10-27, 11-30, and 11-32). PFGE showed that only 1 recurrence (caused by isolate 11-31) was a relapse (caused by isolate [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , and this occurred after a 17-month interval ( figure 3) .
Analysis of relapse versus new infection. PFGE showed that 9 of the 10 recurrences caused by S. marcescens or B. cepacia were new infections ( ), as were 7 of the 8 recurrences P p .001 caused by S. aureus ( ). Of the total 18 recurrences, 16 P p .006 were new infections, and only 2 were relapses. Using a 60% expected relapse rate and the 2-tailed Fisher's exact test, we obtained a P value of !.0001. All of the Serratia isolates were unique, as were 90% of the B. cepacia isolates. Although there was only 1 relapse among the recurrences caused by S. aureus, there was less genotypic variability among the S. aureus strains overall; only 8 different strains were found among the 13 isolates that were tested.
Several of the isolates from recurrences showed similar or identical biochemical phenotypes and antibiotic susceptibility profiles, yet PFGE showed them to be different strains ( figures  1-3) . Two S. marcescens isolates recovered 4 years apart from patient 2 from the same site (isolates 2-4 and 2-5) had identical biochemical codes and antibiotic patterns but were shown to be different strains by PFGE ( figure 1) . Similarly, S. marcescens isolates 3-6 and 3-7 showed the same biochemical phenotype and antibiogram but were unrelated (figure 1). The B. cepacia isolates 5-14 and 5-15 and the S aureus isolates 10-26, 10-27, 11-29, and 11-30 had identical antibiograms within their groups, but the recurrent strains were genotypically different (figure 2). In contrast, B. cepacia isolates were obtained from different lobes of the lung of patient 7 (isolates 7-18 and 7-19) that showed a single biochemical difference but were found to be identical by PFGE. Relapse in this patient was likely to have occurred as a result of inconsistent antibiotic compliance. The single case of S. aureus relapse was caused by isolates that had different susceptibilities to erythromycin and to clindamycin (11-30 and 11-31) but that were shown to be identical by PFGE. The long interval (17 months) between infections with the same strain suggests that the patient had continuous carriage of the strain, eventually leading to reinfection.
In most cases, organisms responsible for recurrent infections did not display greater antibiotic resistance than those causing the initial episodes. All organisms were susceptible to the agent used for prophylaxis, trimethoprim-sulfamethoxazole, except for 2 B. cepacia isolates from patient 6 (6-16 and 6-17) and 1 S. aureus liver isolate from patient 10 (10-28) (tables 2 and 3, respectively). Despite in vitro resistance to trimethoprim-sulfamethoxazole, both of the episodes of B. cepacia pneumonia in patient 6 were successfully treated with regimens that included intravenous trimethoprim-sulfamethoxazole. Only 1 S. aureus isolate displayed oxacillin resistance (isolate 9-25; table 3). In patient 10, PFGE typing of S. aureus showed that on 2 occasions the same strains isolated from liver abscesses were found in skin lesions (data not shown). In patients 9 and 11, the strain of S. aureus found in each liver abscess was also found in the patient's nares. 
DISCUSSION
Recurrent infections caused by organisms of the same species, sometimes with similar or identical antibiotic susceptibility patterns, in patients with CGD have been thought to be due to relapse of persistent, uncleared infection. Molecular genotyping techniques such as PFGE have resulted in more accurate discrimination of strains, thus allowing us to determine whether these recurrent infections are due to relapse or new infection. The assumption that recurrences of infection in patients with CGD were relapses resulting from incomplete eradication of previously infecting organisms had been supported by findings in other patient populations. S. marcescens isolates from patients with recurrent infections studied over the course of a 15-year period showed that 73% of patients (22/30) had isolates genotypically identical by PFGE [10] . Recurrent Pseudomonas aeruginosa pneumonia in patients receiving mechanical ventilatory assistance have been shown to be caused by alreadyresident strains rather than by infection with new strains [11] . P. aeruginosa was also found to persist in the lower respiratory tracts of up to 50% of intubated patients, without any clinical evidence of disease [12] . Persistence of infecting strains of B. cepacia and S. aureus for months to years in patients with cystic fibrosis (CF) has been documented [13] [14] [15] . In a series of 17 patients with CF followed up over a period of 9 years, PFGE showed that B. cepacia infection was due to persistence of unique strains in each patient and not to transmission between patients [16] . Patients who received lung transplants and immunosuppressive therapy also retained the same B. cepacia strain throughout [16] . Molecular typing of pulmonary Mycobacterium avium complex (MAC) infections has shown that, in patients with underlying lung disease (e.g., chronic obstructive pulmonary dis- NOTE. AC, amoxicillin-clavulanic acid; Ak, amikacin; Am, ampicillin; AS, ampicillin-sulbactam; Ce, cefazolin; Cf, cefuroxime; Ci, ciprofloxacin; Cl, clindamycin; Cx, ceftriaxone; Er, erythromycin; Gm, gentamicin; I, intermediately resistant; Im, imipenem; Lv, levofloxacin; Me, meropenem; Ox, oxacillin; PFGE, pulsed-field gel electrophoresis; Pn, penicillin; R, resistant; Rf, rifampin; S, susceptible; Te, tetracycline; TS, trimethoprim-sulfamethoxazole; Va, vancomycin.
a API Staph (bioMé rieux).
ease), the same strain of MAC is isolated repeatedly over time [17] . In a group of 90 patients with disseminated MAC with 68 unique strains, the same strain was recovered from different sites over long periods of time in 95% of the patients, regardless of human immunodeficiency virus infection status [18] . Patients were prone to infection with only 1 strain of MAC, and new infection was uncommon. Long-term nasal colonization with a persistent strain of S. aureus has been implicated as a source of organisms giving rise to bacteremia in hospitalized patients [19] . Persistent strains of S. aureus have also been found in patients receiving hemodialysis, continuous ambulatory peritoneal dialysis, and prolonged intravascular catheterization and in those with surgicalsite infections [20] [21] [22] [23] .
There are only a few precedents for recurrent infection caused by new strains of the same species in other patient populations. Several studies have shown that, among symptomatic recurrences of Clostridium difficile disease, 38%-56% were due to new infection [24] [25] [26] [27] . Using genotyping by restriction fragment-length polymorphism analysis, van Rie et al. [28] showed that 80% of patients without human immunodeficiency virus infection who resided in an area in which tuberculosis was endemic had postprimary tuberculosis caused by new infection, rather than relapse of the initial infection.
Molecular genotyping of isolates from patients with CGD has been hampered by the often long intervals between infections caused by the same species. By storing isolates over several years, we were able to compare patient isolates by analyzing strains from the initial infection and the recurrence together, using the same methods for biochemical profiles, antibiograms, and PFGE. In the present study, 89% of recurrences in patients with CGD were new infections, rather than relapses (P ! ; table 4). Different biochemical profiles correctly inferred .0001 the uniqueness of strains, but strains with identical profiles were not necessarily found to be the same by PFGE. Antimicrobial susceptibility patterns, although often suggestive of differences, also lacked sufficient discriminatory power, which confirms the results of a previous report on gram-negative bacteremia [6] . In contrast to studies of other diseases [29, 30] , the time to recurrence was not predictive of whether infections that occurred in association with CGD were relapses or were new.
Our data conclusively demonstrate that recurrent infections in patients with CGD are most often due to new infection, rather than to relapse. Importantly, neither biochemical patterns nor antibiotic susceptibility data (antibiograms) were reliable predictors of strain difference or identity. Unrelated strains sometimes had the same or similar biochemical or antibiotic profiles, whereas, in several cases, the same strains had differences in either biochemical profile or antibiotic susceptibility. Typing of bacterial isolates by PFGE is currently the only reliable means of distinguishing relapse from new infection, although other molecular analysis-based methods may also be sufficiently discriminatory. We noted that several of the recurrent strains from S. aureus liver infections were resistant to more antibiotics than were the initial isolates (table 3) . Subsequent infection with more-resistant organisms may represent changes in the susceptibility of colonizing organisms as a result of antibiotic therapy. Because nasal carriage of S. aureus is common [31] , it may provide a setting for selection of more-resistant strains, as well as providing a continuing endogenous source of infection. von Eiff et al. [19] found that 82% of hospitalized patients with S. aureus bacteremia had the same strain isolated from both blood and nares. Patients with chronic S. aureus colonization may have greater predisposition to recurrence and reinfection [29] . Despite the expectation that a wide variety of S. aureus strains should be encountered in cultures taken from different individuals, it is known that common strains may be encountered, particularly in hospitals. Although this may explain why the same S. aureus PFGE patterns were found in several different patients in the present study, we cannot exclude the possibility that intrahospital transmission occurred.
The prominence of new infections over relapses in patients with CGD shows that our current therapy for acute infections is effective in most cases. However, prophylaxis is clearly inadequate, because patients still develop new infections, often with the same species. This suggests that more-effective prophylactic guidelines and practices are needed. Concern that resistant organisms may emerge as a result of higher prophylactic dosing may be unfounded; we encountered very little trimethoprimsulfamethoxazole resistance among infecting strains.
Recurrences caused by new strains in patients with CGD suggest that there are differences beyond simple susceptibility to infection between patients with CGD and those with CF or MAC. Although cross-colonization of B. cepacia strains has occurred, most patients with CF are persistently colonized by a unique clonal type [13, 15, 16, 32] . Transient nosocomial acquisition of a second strain may occur in association with an epidemic [33] [34] [35] [36] [37] . Colonization in patients with CF has been attributed to the ability of B. cepacia to survive in hostile environments, as well as its affinity for damaged tissue [38] . In nontuberculous mycobacterial infections, lung injury and host structural abnormalities may also predispose to persistent colonization [11] . Patients with long histories of smoking who have cavitary lung disease tend to be infected for prolonged periods with a single strain of MAC, whereas nonsmokers with multifocal nodular bronchiectasis have been found to be infected with multiple strains [17] . Therefore, patients with underlying chronic lung disease appear to be more susceptible to persistence of the same bacterial strain, whereas patients with immune defects, such as CGD, clear their infections with therapy but remain susceptible to infections with new strains.
There have been no previous attempts to analyze pathogens that cause recurrent infections in patients with CGD. Using PFGE, we have identified new infection as the dominant mode of recurrent infection with both gram-negative and gram-positive organisms in patients with CGD. The fact that patients with CGD acquire multiple infections with different strains of the same few species of limited genera of bacteria (B. cepacia, S. marcescens, and S. aureus) further underscores the unique interaction between the CGD defect and these specific pathogens. The findings of the present study enlarge our fundamental understanding of CGD infections and support our current recommendations for treatment of CGD. However, although the high rate of new infection among patients with CGD indicates that antibiotic therapy is generally adequate to eradicate incident infections, prophylaxis has not been adequate to prevent new ones. These observations suggest that studies of new prophylactic regimens, such as higher-dose trimethoprim-sulfamethoxazole, the use of newer antimicrobials, or increased environmental screening and controls, are needed to further reduce the incidence of severe infections among patients with CGD. Molecular genotyping of bacterial isolates is critical to understanding recurrent infections in patients with CGD.
